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ABSTRACT 
 
Pulmonary surfactant is a complex mixture of lipids and specific proteins found in the alveoli 
and its main role is to reduce the surface tension of the alveolar air/water interface, thereby 
preventing lung collapse. Lack of pulmonary surfactant in premature babies results in lethal 
respiratory distress syndrome (RDS), which is today treated with surfactant replacement 
therapy, i.e. delivery of pulmonary surfactant extracted from animal lungs into the airways. 
Despite the effectiveness of surfactant replacement therapy, it has several limitations: 
pronounced batch to batch variability, risk of disease transmission, and expensive source 
material and production procedures. Moreover, RDS secondary to surfactant inhibition in 
adults (ARDS) has turned out to be difficult to treat with existing natural derived surfactant 
preparations, probably for a combination of reasons, such as limited supply and sensitivity to 
inhibition. The development of synthetic pulmonary surfactants is a tempting solution that 
could overcome these limitations, but in spite of more than 30 years of development work, 
there still no synthetic surfactant in clinical use.  
The two surfactant proteins B (SP-B) and C (SP-C) that are present in natural derived 
surfactants are difficult to produce or replicate and the lipid composition of natural surfactants 
is very complex. As a result, the development of simple lipid compositions and surfactant 
protein analogues that can reproduce the activity of animal derived surfactants is not trivial. In 
this thesis, we designed surfactant protein analogues and tested their activities in animal models 
of neonatal RDS and ARDS. We investigated the importance of intramolecular disulfide bonds 
in an SP-B analogue, and we improved the recombinant production of the SP-C analogue SP-
C33Leu. Artificial surfactant based on recombinant SP-C33Leu improved lung mechanics in 
an RDS model and enhanced lung function and reduced inflammation in an ARDS model. 
Finally, we investigated the novel concept of creating surfactant protein analogues that 
combine both SP-B and SP-C activities in one polypeptide. We designed and recombinantly 
produced polypeptides that fuse an SP-B analogue and an SP-C analogue - Combo peptides - 
and tested mixtures of these analogues with two phospholipid species in an RDS model 
ventilated without stabilizing end expiration pressures in the lung. Mixtures containing low 
amounts of Combo peptides improve lung function in a similar manner as a clinically used 
natural derived surfactant. The Combo peptide approach can deliver simple synthetic 
surfactants that match currently used natural preparations and can be produced efficiently. 
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1 INTRODUCTION 
 
1.1 Background 
The breathing cycle and the tree-like structure of the lungs lay the foundation for gas exchange. 
The airways are branched 23 times (1) from the trachea to the alveoli, producing a large area 
of 50-100 m2 exposed to air in an adult lung, and normal breathing refreshes part of the air in 
the airways and alveoli every 3-5 seconds. There is an air/water interface lining the alveoli and 
since the forces between neighboring water molecules are stronger than the forces between the 
water and the gas phase, a surface tension is created that promotes lung collapse (von 
Neergaard, 1929). However, under physiological conditions surface active agents are able to 
reduce the alveolar surface tension to near zero values, which markedly facilitates lung 
expansion and reduces the efforts of respiration (Gruenwald, 1947). In other words, creation of 
a low alveolar surface tension is a prerequisite for normal lung function (2). 
In the 1950s two researchers, Pattle and Clements, independently identified the surface-active 
agent referred to as lung or pulmonary surfactant, which reduces the surface tension of the 
air/water interface in the mature alveoli (3, 4). Shortly thereafter, the lack or insufficient 
amounts of lung surfactant was associated to what was then called hyaline membrane disease 
by Avery and Mead (5). The hyaline membrane disease is nowadays known as respiratory 
distress syndrome (RDS) and is primarily associated with premature birth, usually before 30 
gestational weeks, when the babies have immature lungs that are not able to produce sufficient 
amounts of lung surfactant. Even though the cause of RDS was established at this time, the 
development and clinical implementation of a treatment of this lethal condition took over two 
decades. 
The first attempts to treat RDS in clinical trials employed instillation of 
dipalmitoylphosphatidylcholine (DPPC) based lipid mixtures, and were unsuccessful (6). Even 
though DPPC is the major component of pulmonary surfactant and is able to reduce surface 
tension to low values in vitro, it needs to be combined with proteins and other phospholipids 
to show rapid enough spreading properties in vivo (7). In 1972 Enhorning and Robertson 
showed that tracheal instillation of natural-derived surfactant, extracted from adult animal 
lungs was able to increase lung expansion in premature rabbits (8).  
The first successful clinical study with human babies with RDS using bovine natural-derived 
surfactant instillation was performed just a few years after the first demonstration of efficacy 
in animals, and was published in 1980 by Fujiwara and coworkers (9). At about the same time, 
 2 
at Karolinska Institutet Robertson and Curstedt developed a surfactant preparation derived 
from porcine lung, which is nowadays known under the name Curosurf® (10). Curosurf® was 
tested successfully in randomized clinical trials in the 1980s, which proved the efficacy and 
optimal dosage against neonatal RDS (11, 12). Several other natural derived pulmonary 
surfactant preparations, for example Survanta®, Infasurf® and Alveofact®, prepared from 
different animal sources, purified in slightly different ways, and with somewhat different 
compositions in terms of phospholipid profiles and protein contents, were also developed and 
tested successfully in clinical trials, see (13-22). Natural derived surfactant preparations are 
still in clinical use, having saved the lives of thousands of babies per year worldwide since their 
introduction. There are still, however, several reasons to develop synthetic lung surfactants for 
treatment of RDS, which will be described further below. 
 
1.2 Lung surfactant biosynthesis  
In the alveolar region we can observe three major types of cells: alveolar macrophages and type 
I and type II alveolar epithelial cells. The macrophages take part in lung host defense and can 
phagocytize inhaled particles, invading microorganisms, and also remnants of alveolar 
pulmonary surfactant (23). The alveolar type I epithelial cells form the main part of the alveolar 
wall. They are elongated and thin cells that contribute most of the alveolar surface area (90-
95%) and mediate the diffusion of gas between inhaled air and the pulmonary capillaries (24). 
The alveolar type II cells make up the remaining 5-10% of the alveolar wall, are globular in 
shape and, importantly, produce and secrete lung surfactant components (25). 
In the alveolar type II cells, pulmonary surfactant lipids and proteins are synthesized in the 
endoplasmic reticulum (ER), transferred to the Golgi apparatus for modifications like 
attachment of glycosyl moieties, and then transported to multivesicular bodies (MVB), which 
eventually mature into the intracellular storage form of surfactant - lamellar bodies (LB) (26) 
(Figure 1). As the name implies, the MVB are vesicles where the outer membrane invaginates 
and forms smaller vesicles within, the MVB is thus a vesicle with multiple vesicles inside. 
During the formation of the MVB, the complex and unique lipid and protein composition of 
pulmonary surfactant is established. The LB are onion-like structures in the sense that they 
contain multiple tightly packed phospholipid bilayers. The LB are transported out of the 
alveolar type II cells and into the alveoli by exocytosis, where the densely packed bilayers 
unpack, and turn into a more loosely organized network called tubular myelin (TM). Eventually 
the pulmonary surfactant phospholipids will form a monolayer at the air/water interface, in 
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which the hydrophobic phospholipid fatty acyl tails face air and the hydrophilic phospholipid 
head groups face the water layer (27). (Figure 1) 
 
 
Figure 1. Alveolar components and pulmonary surfactant production. The alveolus is defined 
by and contains three different types of cells: alveolar macrophages that phagocytize particles 
including residual surfactant and microorganisms, alveolar type I cells that mediate oxygen 
and carbon dioxide diffusion and form the major part of the alveolar wall, and alveolar type II 
cells that produce and secrete pulmonary surfactant. Pulmonary surfactant is produced in the 
endoplasmic reticulum (ER) and travel through the Golgi apparatus to form multivesicular 
bodies (MVB) and eventually lamellar bodies (LB). The LB are transported out of the cell by 
exocytosis, where after the tubular myelin (TM) is formed and eventually phospholipids, and 
probably proteins, form a monolayer at the air/water interface. 
 
1.3 Lung surfactant composition  
The composition of the surface-active pulmonary surfactant was initially believed to be only 
lipids until, in the 1970s, small amounts of proteins were observed in natural surfactant (7, 28). 
Years later the hydrophobic surfactant protein (SP)-B and SP-C were shown to be part of the 
organic solvent extracts of lung tissue or bronchoalveolar lavage that were used to produce 
natural derived surfactant preparations (29). Nowadays is known that pulmonary surfactant 
Alveolar type II cell
Alveolar type I cell
ER
Macrophage 
Golgi apparatus
MVB
LB
TM
Alveolar fluid
Air
 4 
obtained by bronchoalveolar lavage of mammals consists of about 80% (w/w) phospholipids, 
10% neutral lipids (mostly cholesterol) and 10% proteins (30) (Figure 2).  
 
Figure 2. Composition of pulmonary surfactant. DPPC, dipalmitoylphosphatidylcholine; 
PC: phosphatidylcholine; PG: phosphatidylglycerol; PL, phospholipids; SP-A, -B, -C, -D, 
surfactant protein -A, -B, -C, -D. The percentages are by mass.  
 
Phospholipids are amphiphilic molecules, i.e. they have one polar part and one non-polar part, 
that consist of a glycerol skeleton linked to one hydrophilic phosphate group, which in turn is 
esterified with an alcohol group, and to two hydrophobic fatty acyl chains. The fatty acyl chains 
are linked via hydroxyl esters to glycerol and contain either only single bonds (saturated fatty 
acyl chains) or contain also carbon-carbon double bonds (unsaturated fatty acyl chains). The 
different combinations that can be formed by esterifying the phosphate group at position 3 of 
the glycerol moiety with one of five alcohols (glycerol, choline, ethanolamine, serine or 
inositol) combined with the attachment of different fatty acyl tails to positions 1 and 2 of the 
glycerol moiety result in that more than 50 different phospholipid species are found in lung 
surfactant of mammals (31). However, the main single component of lung surfactant (about 
40% by mass) is DPPC, which is present only in minimal amounts in other phospholipid 
DPPC
40%
Unsaturated PC
25%
PG
10%
Other PL
5%
Neutral lipids
10%
SP-A
5%
SP-B
2%
SP-C
2%
SP-D
1%
90% Lipids
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membranes, and therefore the high percentage of DPPC is in principle unique to lung 
surfactant. DPPC contains two saturated fatty acyl chains (palmitoyl groups, with 16 carbon 
atoms) (Scheme 1) and is mainly responsible for reducing the surface tension at the alveolar 
air/water interphase. Pulmonary surfactant also contains about 25% by mass of unsaturated 
phosphatidylcholine (PC) species, 10% of phosphatidylglycerol (PG) species and about 5% of 
other phospholipid species (phosphatidylinositols, phosphatidylserines and 
phosphatidylethanolamines) (32). The high percentage of PG species is, like the high DPPC 
content, an apparently unique feature of lung surfactant compared to other phospholipid 
membranes, and strongly suggest that these phospholipids have specific and important 
functions that are necessary for lung surfactant activity. 
 
 
Scheme 1. Molecular structure of the saturated phospholipid DPPC. DPPC is the most 
abundant molecule in pulmonary surfactant and has a melting temperature of 41°C, which 
means that DPPC bilayer membranes are too rigid for efficient spreading in the alveoli at 
physiological body temperatures of mammals, but DPPC can efficiently reduce surface tension 
under in vitro conditions when the rate of spreading is not limiting.  
 
The protein content in pulmonary surfactant is divided between four specific proteins: about 
6% by mass of the pulmonary surfactant dry weight is made up of the multimeric and 
hydrophilic proteins SP-A and SP-D and about 4% of lung surfactant mass is made up of the 
comparatively small and hydrophobic proteins SP-B and SP-C (30, 33-36) (Table 1). 
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Table 1. Characteristics of lung surfactant proteins 
 
 
1.4 LUNG SURFACTANT PROTEINS A AND D  
SP-A and SP-D belong to the collectin (collagenous lectin, i.e. carbohydrate-binding proteins) 
family and are expressed in the lung, primarily in the alveolar type II cells but also in upper 
airways and so called Clara cells and in other organs and tissues like the gastric and intestinal 
mucosae (37, 38). SP-A and SP-D may have several different functions in lung surfactant, SP-
A for example binds to the crossings in TM. However, the main function of both SP-A and 
SPD is in lung immunity, i.e. to take part in the defense against invading pathogens. SP-A and 
SP-D are comparatively big water-soluble proteins that can bind to pathogens through their C-
terminal carbohydrate recognition domains (CRD) that form globular head groups (39, 40). 
Both the pulmonary collectins are oligomers formed by joining several trimeric units together; 
SP-A is composed of six trimers, i.e. totally 18 subunits of ~35 kDa each (41, 42), while SP-D 
is built up by four trimers, i.e. totally 12 subunits of ~43 kDa each (43, 44). The SP-A and SP-
D activities in the innate pulmonary immune response are manifold; they stimulate chemotaxis, 
promote phagocytosis and contribute to aggregation and opsonization of pathogens (45). SP-A 
has also been shown to participate in the uptake and secretion of surfactant from alveolar type 
II cells, as well as in the formation of TM, while SP-D has shown to contribute to the surfactant 
homeostasis (46, 47). SP-D deficiency is associated to an increased concentration of surfactant 
in lung cells and the alveolar space (48, 49). Neither SP-A nor SP-D apparently has any direct 
role in reducing surface tension in the alveoli (50), which is indirectly supported by the fact 
that they are not present in natural derived surfactant preparations (29, 51). The surfactant 
preparations derived from animal origins used for exogenous replacement therapy are obtained 
by one or several purification steps in organic solvents, which results in that the hydrophilic 
SP-A and SP-D are efficiently removed, while phospholipids, SP-B and SP-C remain soluble. 
Solubility 
properties
Monomer 
mass
Protein 
subunits Family Main role
Dry weight in 
native surfactant
SP-A Hydrophilic ~35 kDa 18 Collectin innate pulmonary immune response ~5 %
SP-B Hydrophobic 8.7 kDa 2 Saposin-like  reduce surface tension in the alveoli ~2 %
SP-C Hydrophobic 4.2 kDa 1 - reduce surface tension in the alveoli ~2 %
SP-D Hydrophilic ~43 kDa 12 Collectin innate pulmonary immune response ~1 %
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Therefore SP-B and SP-C are the target proteins for development of synthetic lung surfactant 
preparations and the main focus of the present thesis. 
 
1.5 Lung surfactant proteins B and C  
SP-B and SP-C are small lipid-associated polypeptides that are important for lowering the 
surface tension in the alveoli (51). SP-B and SP-C are synthesized in the type II alveolar cells 
from different precursor proteins that go through multiple proteolytic cleavages and other 
posttranslational modifications as they traverse the Golgi apparatus, MVB and LB (52-55). The 
above facts as regards overall properties of SP-B and SP-C may suggest that they also are 
structurally and functionally similar. This is however not the case: SP-B and SP-C are 
structurally completely unrelated, and they apparently perform different functions in lung 
surfactant (56-62). 
 
1.5.1 Surfactant protein B 
The native SP-B molecule consists of a polypeptide chain with 79 amino acid residues, that is 
covalently linked into a homodimer with a total molecular weight of 17.4 kDa (58, 63). The 
primary structure of SP-B is characterized by the presence of seven cysteines, six of which 
form three intra-molecular disulfide bridges (Cys8 to Cys77, Cys11 to Cys71 and Cys35 to 
Cys46) and Cys48 that forms an inter-molecular disulfide bridge with a second subunit, 
resulting in the covalently linked homodimer (60, 64). The tertiary structure of SP-B has not 
been experimentally resolved, however it is known that it has a high α-helical content in lipid 
environments and in organic solvents, as determined using circular dichroism (CD) and Fourier 
transform infrared (FTIR) spectroscopy (65-69). SP-B belongs to the saposin-like protein 
(SAPLIP) superfamily and the structural homology between proteins from this family 
combined with experimental structural studies of other SAPLIP members, have given some 
important insights into the SP-B structure. Modeling studies using NK-lysin (70) and saposin 
B (71), for which there are experimentally determined NMR and X-ray structures, respectively, 
suggested that the SP-B structure contains 4-5 α-helices folded into a V-shape arrangement 
with helices 1 and 5 on one side, helices 2 and 3 on the other side and helix 4 in between (Figure 
3). It should be pointed out that SP-B differs in some aspects from the other SAPLIP members: 
it is a dimer, soluble in organic solvents, whereas the other members are water-soluble 
monomeric proteins. This makes modeling of SP-B based on other SAPLIP structures difficult 
and all models proposed should be interpreted with caution. The covalent disulfide-linked 
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nature of SP-B puts some constraints on what parts of the two subunits are close, and based on 
this the SP-B homodimer has been suggested to be promoted by salt bridges at the subunit 
interface, created between the charged residues Glu51 and Arg52 from different subunits (70). 
 
 
Figure 3. Hypothetical structural model of monomeric SP-B. Cartoon representation of the 
polypeptide backbone structure of the SP-B homologous protein NK-lysin from pig. The 
hypothetical intra- and inter-molecular disulfide bonds are represented with red lines. N and 
C indicate the N- and C- terminus of the peptide respectively. PDB code 1NKL (72).  
 
In native SP-B, the net charge of +14 (9 positively and 2 negatively charged residues per 
subunit) and the about 60% of the amino acid residues with strictly hydrophobic side chains 
are likely important for its strong interaction with lung surfactant phospholipids (73). In spite 
of the overall hydrophobic nature and requirement of organic solvents for solubilization, SP-B 
attaches only peripherally to bilayers of phospholipids and lacks transmembrane regions (74, 
75). The detailed molecular mechanisms of SP-B function in pulmonary surfactant are still 
N
C
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unknown. However, the dimeric nature and ability of SP-B to interact with the outer parts of 
phospholipid membranes can make it able to cross-link two different phospholipid layers (62, 
70, 76, 77). Such interactions of SP-B could promote dense phospholipid bilayer packing, 
induce fusion and lysis of phospholipid layers as well as mediate transport of phospholipids 
between membranes. Dense packing of layers of pulmonary surfactant phospholipids, possibly 
mediated by SP-B, can be beneficial in formation of the densely packed LB and also help to 
stabilize different phospholipid layers at the end of expiration (62, 78). The ability to fuse or 
lyse phospholipid layers has been observed for isolated SP-B segments (79) and under 
physiological conditions, such actions of SP-B could promote fast adsorption of phospholipids 
to the air/water interphase during dynamic respiratory cycling (34, 80). It has also been 
suggested that SP-B dimers can associate to form larger oligomers with a ring-shape, which 
could promote the transport of phospholipids between layers (71). 
ProSP-B is the precursor protein of SP-B, which undergoes glycosylation outside the SP-B 
region. ProSP-B consists of 381 residues, has a molecular weight of 42 kDa and is synthesized 
into the ER, directed by the presence of a signal peptide (63). The subsequent maturation 
process occurs in the Golgi apparatus and possibly in the MVB and it is mediated by at least 
three different proteolytic enzymes: napsin A, cathepsin H, and pepsinogen C (53, 81). The 
details of the proteolytic maturation are still uncertain. Mutations in the SFTPB gene (that 
encodes proSP-B) in humans as well as in mouse models are associated with SP-B deficiency, 
which causes lethal RDS in the neonatal period (82-84). SP-B deficiency is linked to an 
aberrant processing of proSP-C (see further below) that results in formation of an inactive, 
misprocessed SP-C variant that is secreted into the extracellular alveolar space and accumulates 
in the alveoli (85, 86). Lung transplantation is currently the only available treatment for SP-B 
deficiency caused by SFTPB mutations (26). 
 
1.5.2 Surfactant protein C 
SP-C is a 35 amino acid residue lipopeptide and has a molecular weight of 4.2 kDa (59, 61). It 
is a cationic peptide with a net charge of +3 and it is probably the most hydrophobic protein so 
far described in mammals since it consists of about 80 % amino acid residues with hydrophobic 
side chains and it contains one or two (depending on animal species of origin) covalently 
attached fatty acyl chains to Cys5 and/or Cys6 via thioester bonds (87, 88). SP-C does not 
belong to any known protein family and is exclusively expressed by the alveolar type II cells. 
The tertiary structure of porcine SP-C dissolved in organic solvents was described in 1994 and 
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shows one long α-helix that makes up the C-terminal two thirds of the peptide and a structurally 
disordered N-terminal part (89) (Figure 4). More specifically, the α-helix is composed of 
residues 9-34 and its length of 37Å perfectly matches the thickness of a fluid DPPC bilayer 
(90). Also, the length of the helix segment that contains only non-polar residues matches the 
thickness of the hydrophobic fatty acyl part of a DPPC phospholipid bilayer (90). These 
correlations strongly suggest that SP-C is inserted in a transmembrane orientation in a 
phospholipid (DPPC) bilayer, whereby the non-polar residues of the α-helix are positioned to 
interact with the hydrocarbon chains of the phospholipids, and the positively charged residues 
Lys11 and Arg12 are suitably located to interact with the polar phospholipid head groups (90). 
It has been suggested that SP-C could alternatively interact with phospholipids in a monolayer, 
like the monolayer supposedly located at the alveolar air/water interface, by adopting a tilted 
position of about 70° (91).  
 
  
Figure 4. Human SP-C structure. Three-dimensional structure of the polypeptide backbone 
of human SP-C determined in a mixed solvent containing C2H3Cl/C2H3OH/ 1 M HCl 32:64:5 
(by volume). The portion of the structure marked in red represents the location of the 
cysteines that are palmitoylated in native SP-C. N and C indicate the N- and C- terminus of 
the peptide respectively. PDB code: 1SPF (89). 
 
The α-helix of SP-C contains a high number of valines that are prone to form β‐sheet aggregates 
in vitro resulting in amyloid-like fibrils (92, 93). The dominance of Val residues in the SP-C 
α-helix is unexpected, since Val has the highest b-strand propensity of all 20 naturally 
occurring gene-encoded residues (92, 93). This feature is unique to SP-C and the reason why 
its α-helix contains a poly-valine region is unknown, however several possible explanations 
N
C
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have been suggested. The poly-valine α-helix confers a very stable and rigid structure that could 
be used to promote rapid adsorption by perturbing the phospholipid layers (90, 94). Another 
possible explanation is that amyloid fibrils are formed under certain conditions, promoted by 
the high b-strand propensity of Val and that they play a physiological role, for example, in the 
defense against bacteria or viruses (95), in a similar manner as certain defensins can form 
fibrillar nets in the gastrointestinal tract in the defense against bacteria (96, 97).  
The precursor protein of SP-C, proSP-C contains a BRICHOS domain that prevents the 
aggregation and misfolding of the SP-C part during biosynthesis (98-100). The BRICHOS 
domain is able to bind nonhelical poly-valine segments and to promote their folding into helical 
conformations (98, 101, 102). In addition to its physiological target peptide, the BRICHOS 
domain has turned out to be able to prevent amyloid formation also of other proteins, for 
example amyloid-b (Aβ) and islet amyloid polypeptide (IAPP) (103-107). These features make 
the BRICHOS domain an interesting candidate for development of therapeutic strategies 
against amyloid diseases, in particular the BRICHOS domain from the Bri2 protein seems to 
have properties that can be harnessed against neurodegenerative diseases (103, 108, 109).  
ProSP-C is a 21 kDa protein of 197 amino acid residues, cotranslationally inserted into the ER 
membrane and transported to the Golgi apparatus where it is palmitoylated (110). During the 
maturation process, proSP-C is cleaved by several enzymes (111-113), eventually releasing the 
mature form of SP-C, which like SP-B ends up in the extracellular alveolar space after secretion 
together with phospholipids in the LB. Again, although SP-B and SP-C are overall similar in 
being secreted together with phospholipids, the details differ. ProSP-C gets membrane-inserted 
already into the ER, where the SP-C part acts as a signal peptide and is then transported and 
processed all the way to the alveoli as an integral membrane protein (110, 114). ProSP-B, in 
contrast, is translocated into the ER lumen, directed by a traditional, N-terminally located signal 
peptide that is removed after translocation to the ER lumen, and the proteolytically released 
SP-B part becomes associated with surfactant membranes at a later stage, probably in the MVB 
(52, 115, 116).  
Mutations in the gene encoding proSP-C, SFTPC, are more common than mutations in SFTPB 
and most of them are located in the BRICHOS domain (100, 117). SFTPC mutations result in 
lack, or reduced levels, of mature SP-C and also result in aberrant protein folding and (pro)SP-
C aggregation and amyloid fibril formation. Misfolding of (pro)SP-C associated with SFTPC 
mutations results in disease, with different degrees of pathology, from mild interstitial lung 
disease (ILD) to severe pulmonary fibrosis (100, 118-122). Notably, mutations in SFTPC, in 
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particular those that affect the BRICHOS domain, result in amyloid disease in early infancy, in 
contrast to other amyloid diseases, which do not affect humans until late life. This attests to the 
extreme amyloidogenic potential of the (pro)SP-C poly-Val segment. Interestingly, pulmonary 
surfactant from birds does not contain SP-C and is less effective in lowering the surface tension 
in vitro than surfactant from mammals. Bird lungs have a different physiology and morphology 
compared to mammalian lungs. Therefore, the function of bird surfactant is not to prevent 
alveoli from collapsing but to keep the air capillaries open (123). 
 
1.6 Neonatal and acute respiratory distress syndrome 
Respiratory distress syndrome (RDS) in neonates is characterized by insufficient amounts of 
pulmonary surfactant and results in respiratory failure. The lungs of more than about 10 weeks 
prematurely born infants are simply not prepared to breathe air and have an underdeveloped 
surfactant system. The lack of pulmonary surfactant is associated with alveolar collapse and 
with concomitant difficulties in oxygenation and damage to the alveolar epithelium including 
the surfactant producing type II cells, which results in a vicious cycle (124). The by far most 
common reason for the lack of sufficient pulmonary surfactant in prematurely born neonates is 
that their immature lungs are unable to produce sufficient amounts of pulmonary surfactant. 
Genetic defects can also affect pulmonary surfactant function, and mutations in the genes 
encoding proSP-B (SFTPB) or ABCA3, a phospholipid transporter present in LB can give rise 
to neonatal RDS in full term infants (125). RDS is a life-threatening disease and the 
development of surfactant replacement therapy with natural derived surfactant preparations in 
the 1980s have saved millions of lives (95).  
Another condition associated with pulmonary surfactant dysfunction is acute respiratory 
distress syndrome (ARDS), also referred to as acute lung injury (ALI). The pathogenesis 
behind reduction of pulmonary surfactant activity in ARDS, where surfactant inhibition is a 
prime cause, differs qualitatively from that in neonatal RDS, where surfactant deficiency is the 
main underlying factor (Table 2). ARDS can be elicited by several different conditions, 
including direct lung injury, for example pneumonia or aspiration of toxic substances, or be a 
result of severe systemic diseases, for example sepsis or multitrauma (126). ARDS can occur 
in individuals of all ages and is associated with high mortality, up to 40%, the exact risk 
depending on the severity and nature of the underlying condition (127, 128). ARDS is 
characterized by bilateral pulmonary infiltrates and arterial hypoxemia identified when the 
partial pressure of arterial oxygen (PaO2) divided by the inspired fraction of oxygen (FiO2) is 
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equal to or less than 300 mmHg (PaO2/FiO2 ≤ 300 mmHg) (129). The infiltrates and hypoxia 
are a result of a pulmonary edema that releases blood proteins and other molecules in the 
alveolar space, altering the gas exchange and reducing the pulmonary surfactant activity (130). 
The pathology of ARDS is more complicated than the surfactant deficiency in RDS and despite 
the study of numerous therapies to treat ARDS (surfactants, glucocorticoids, antioxidants) there 
is still no specific treatment (131-134). The surfactant activity in ARDS can be impaired by 
reducing the adsorption of the surfactant to the air/water interface (by blood proteins), changing 
the composition of the surfactant (by fatty acids and phospholipids) and/or chemically altering 
the phospholipids and proteins of the surfactant (by phospholipases, proteases and reactive 
oxygen and nitrogen species) (135-138). The development of a surfactant preparation that is 
more resistant to inactivation and increasing the concentration of active pulmonary surfactant 
by instilling high amounts of exogenous surfactant in the patient could contribute to the 
development of a successful therapy for ARDS.  
 
Table 2. Prominent features of neonatal and acute RDS. 
 
 
1.7 Surfactant replacement therapy  
The most effective and only commercially available drug treatment for neonatal RDS is 
surfactant replacement therapy, using natural derived surfactant preparations from bovine or 
porcine lungs. These preparations contain phospholipids and the hydrophobic surfactant 
proteins SP-B and SP-C (29, 51).  
Today different natural derived surfactants are approved. In USA five surfactant preparations 
have FDA approval but the two synthetic surfactants colfosceril palmitate (Exosurf®) and 
Lucinactant (Surfaxin®) are not commercially available any longer in contrast to the three 
Neonatal RDS Acute RDS (ARDS)
Age of patient Neonate Any age
Caracterized by Insufficient pulmonary surfactant Inactivation of pulmonary surfactant
Causes
Prematurity of the lungs or mutations in precursors of 
surfactant proteins or proteins related to the surfactant 
production
Direct lung injury (for example: pneumonia or aspiration of 
toxic substances) or severe systemic diseases: (for 
example: sepsis or multitrauma)
Treatment Surfactant replacement therapy Supportive care and protective ventilationTreatment of comorbidities
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natural derived surfactants: beractant (Survanta®), calfactant (Infasurf®), and poractant alfa 
(Curosurf®) (Table 3). In other countries bovactant (Alveofact®) and/or surfactant-TA 
(Surfacten®) are available.  
 
Table 3. Composition of natural derived surfactants approved by FDA 
 
 
As described above, the natural derived surfactants provide an effective therapy of neonatal 
RDS. However, their production is costly, there is a limited supply, the rather crude preparation 
methods may give batch to batch variability, and there is a theoretical risk of transmitting 
infectious diseases. These drawbacks motivate the attempts to complement or replace the 
natural derived surfactant preparations with fully synthetic alternatives, which have been 
ongoing since the 1980s. Nevertheless, the development of synthetic surfactant alternatives that 
are at least as effective as the natural surfactants and that can be produced at low cost has turned 
out to be a significant challenge (95).  
Surfactant replacement therapy with natural derived surfactants to treat ARDS, although 
attractive from a theoretical point of view, has been inefficient in clinical trials, mostly due to 
surfactant inactivation (131). Synthetic surfactants that could be efficiently produced at a large 
scale, and possibly made more resistant to inactivation than the natural derived counterparts 
Poractat alfa Beractant Calfactant
Commercial name Curosurf® Survanta® Infasurf®
Preparation Minced porcine lung extract Minced bovine lung extract Bovine lung lavage
PL (mg/ml) 76 25 35
Disaturated PC (mg/ml) 30 11-15.5 16
Total proteins (mg/ml) 1 0.1-1 0.65
SP-B        (mg/ml) 0.45 Not specified 0.26
SP-C       (mg/ml) 0.59 Not specified 0.39
Dose (mg/kg) 100-200 100 100
Volume 1.25-2.5 ml/kg 4 ml/kg 3 ml/kg
FDA approval 1999 1991 1998
PL, phospholipid; FDA,  Food and Drug Administration
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are therefore good candidates for the development of a surfactant preparation that can be used 
to treat ARDS patients (139-141).  
1.8 Synthetic lung surfactant protein analogues 
Endogenous surfactant has a very complex and diverse composition that is difficult to replicate 
faithfully in synthetic preparations. The first synthetic surfactant preparations developed 
contained only phospholipids, primarily a large fraction of DPPC and they were not efficient, 
because DPPC has a high melting temperature (41°C) and does not spread efficiently under 
physiological conditions (142). An active surfactant with good surface activity and efficient 
spreading properties therefore needs to combine DPPC with other phospholipids and with 
proteins in order to lower the melting temperature and promote spreading. Much effort has 
been put into finding a simple phospholipid composition that can be used to produce synthetic 
pulmonary surfactants, but still there is no consensus on what is the optimal composition (143, 
144). In addition, as described above, SP-B and SP-C are structurally and likely also 
functionally distinct, and in line with this notion both proteins are necessary for the optimal 
function of reconstituted surfactant preparations in animal models of RDS (56, 57). However, 
native SP-B and SP-C are difficult to produce due to several factors, including complex intra- 
and intermolecular disulfide linkages, strict hydrophobicity, posttranslational modifications in 
the form of thioester-linked fatty acyl chains, and a pronounced tendency to aggregate. In fact, 
with the exception of recombinant SP-C (145), production of functional SP-B, independent of 
production method (recombinant or synthetic), or synthetic SP-C has not been reported to date. 
Attempts have been made, but it was for example shown by fluorescence anisotropy that native 
SP-B and synthetically produced full length SP-B interact differently with lipid bilayer surfaces 
(146). For these reasons, the development of functional SP-B and SP-C analogues that can be 
produced in a robust manner is needed. 
 
1.8.1 SP-B analogues 
Attempts to produce recombinant full length SP-B fused to urokinase (147) or in the proprotein 
form (148) have been made, however the produced proteins’ abilities to reduce surface tension 
has to our knowledge not been published. Given the structural complexity of native SP-B, 
development of SP-B analogues has to a large extent aimed to reproduce its function but using 
less complex peptide designs. The studies of small linear peptide fragments of SP-B have 
helped to understand the structure-function relationships of individual regions of the SP-B 
polypeptide chain. The fragment corresponding to residues 7-22 that comprise the first helix 
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induce liposome lysis. A longer fragment, corresponding to residues 1-22, was shown to 
promote lipid mixing, but only when the peptide included also parts corresponding to helix 2 
(residues 1-37) it was able to induce liposome fusion. Neither the C-terminal fragment (residues 
43-79) nor the synthetic full length SP-B were able to enhance the fusogenic activity shown by 
the N-terminal half alone (79). From these results it was concluded that the N-terminal half of 
SP-B is the main responsible region for SP-B ability to fuse and lyse phospholipid membranes, 
and also to reduce surface tension in vitro. Another study showed that dimerization of the SP-
B fragment containing residues 1-25, mediated by a disulfide bridge, resulted in a peptide that, 
when mixed with phospholipids, was more efficient in reducing surface tension in vitro than 
the monomeric form, and it was comparable in vitro to native SP-B (149). The results of this 
study support the concept that SP-B function relies to some extent on a homodimeric nature 
and also points to the importance of the presence of at least two helices in SP-B analogues.  
Walther and Waring designed a 34-residue SP-B analogue called Mini-B, which is composed 
of a linear polypeptide corresponding to residues 8-25 and 63-78 of native SP-B (150). These 
two polypeptide segments correspond to the first and last predicted helices of SP-B, which are 
overall hydrophobic but contain 4 and 3 positive charges, respectively. The tertiary structure 
of Mini-B in sodium dodecyl sulfate (SDS) micelles determined by NMR spectroscopy shows 
that the two predicted helices indeed form a helix-loop-helix hairpin stabilized by two 
intramolecular disulfide bonds (corresponding to Cys8-Cys77 and Cys11-Cys71 in native SP-
B) (151) (Figure 5). Synthetic surfactant created by combining phospholipids and Mini-B 
showed comparable activity in vitro and better performance in a rat model of surfactant 
deficiency than a mixture of phospholipids and native SP-B (150). Mini-BLeu is an SP-B 
analogue that is similar to Mini-B except that two methionines have been substituted by 
leucines to promote hydrophobicity and to avoid unintentional oxidation of the methionines 
(143).  
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Figure 5. Three-dimensional structure of the SP-B analogue Mini-B. Cartoon representation 
of the polypeptide backbone of Mini-B where the disulfide bonds are marked in red. N and C 
indicate the N- and C- terminus of the peptide respectively. PDB code: 2DWF (151). 
 
Later studies suggested an important role for the N-terminal 7 residues of SP-B, which are not 
included in Mini-B (152). The analogue formed when these 7 residues were linked to Mini-B 
in one polypeptide was referred to as Super Mini-B (141). The 7-residue N-terminal motif is 
very hydrophobic, and its presence in Super Mini-B, or native SP-B, could thus favor 
interactions with phospholipid membranes of synthetic and native pulmonary surfactant, 
respectively. CD spectroscopy of a peptide corresponding to only the 7 N-terminal residues of 
SP-B suggest a lack of α-helical structure and the possibility of random coil or b-sheet 
structures. This correlates with the presence of three prolines that can prevent helix formation. 
Moreover, Super Mini-B has an α-helical content observed by CD spectroscopy that is similar 
to that of Mini-B (152), a result which further supports that the N-terminal seven residues lack 
stable secondary structure also when they are part of Super Mini-B. At submicellar 
concentrations of SDS Super Mini-B is a more stable non-covalent dimer than Mini-B, and it 
thus more resembles the dimeric structure of native SP-B (141). In addition, Super Mini B 
mixtures with phospholipids have been shown to be more active than Mini-B mixtures in vitro 
and in vivo (140, 141). 
In order to create a more stable and, in particular easier to manufacture SP-B analogue, the 
analogue B-YL was produced, in which the four Cys of Super Mini B were substituted by Tyr 
and the two Met were replaced by Leu. B-YL showed good surface activity in vitro and the 
N
C
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mixture of B-YL with synthetic phospholipids resulted in similar oxygenation and compliance 
as Curosurf® in a surfactant deficiency adult rabbit model (153).  
A different type of analogue designed based on SP-B is called KL4. KL4 is a linear peptide 
formed by the pentapeptide segment LysLeuLeuLeuLeu repeated four times and ending with 
a Lys (Table 4). This results in a 21-residue peptide that is rather straightforward to synthesize 
due to its lack of Cys and that forms an α-helix (154). The KL4 design was reportedly based 
on features of the C-terminal part of SP-B and it was supposed to interact with superficial parts 
of phospholipid membranes, like SP-B (154). This hypothesis has been questioned based on 
results that showed that the KL4 helix is localized in a transmembrane manner in phospholipid 
bilayers, thus more resembling SP-C (155, 156). Synthetic surfactant preparations based on 
KL4 have shown promising results in vitro and in vivo (157-160). A synthetic surfactant 
preparation, called Lucinactant (Surfaxin®), containing KL4 mixed with mainly synthetic 
phospholipids but also palmitic acid was approved by the US Federal Drug Administration in 
2012 for prevention of RDS in premature infants, after conduction of successful clinical trials 
(161). However, the company ceased with the production of Surfaxin® as part of a restructuring 
plan.  
Several other molecules have been reported to behave as functional analogues of SP-B, for 
example polymyxin E (70) and peptoids (162). These analogues are not further described here 
since our studies have been focused on conventional L-amino acid peptide-based analogues, 
which have the advantage that they can be produced by recombinant methods. 
 
Table 4. Comparison of amino acid sequences of human SP-B and SP-B analogues. The 
sequence differences of the SP-B analogues from the human SP-B are marked in red. 
 
Polypeptide Sequence
1         10          20             30                40          50               60          70
Human SP-B FPIPLPYCWLCRALIKRIQAMIPKGALAVAVAQVCRVVPLVAGGICQCLAERYSVILLDTLLGRMLPQLVCRLVLRCSM
Mini-B -------CWLCRALIKRIQAMIPKG-------------------------------------GRMLPQLVCRLVLRCS-
Mini-BLeu -------CWLCRALIKRIQALIPKG-------------------------------------GRLLPQLVCRLVLRCS-
Super Mini-B FPIPLPYCWLCRALIKRIQAMIPKG-------------------------------------GRMLPQLVCRLVLRCS-
B-YL FPIPLPYYWLYRALIKRIQALIPKG-------------------------------------GRLLPQLVYRLVLRYS-
KL4 ----------------------------------------------------------KLLLLKLLLLKLLLLKLLLLK
  19 
 
1.8.2 SP-C analogues 
Native SP-C is difficult to obtain both by chemical synthesis and by recombinant production 
due to the pronounced propensity of the poly-valine segment to form b-sheet aggregates instead 
of the native α-helix. However, it has been shown that production of recombinant human SP-
C with the two palmitoylated Cys substituted by Phe can result in a helical peptide (163). A 
synthetic surfactant called Lusupultide (Venticute®) containing this recombinant version of SP-
C, rSP-C and a synthetic phospholipid mixture improved lung function in animal models (163-
166), and was tested in clinical trials for efficacy against ARDS, but turned out not to show 
significant positive effects (139, 167). A lot of effort has likewise been put into designing active 
SP-C analogues that avoid b-sheet formation, by modifying the poly-valine sequence. After 
observing a high helical content, no aggregation and a good in vitro surface activity of an SP-
C analogue where the entire poly-valine region was substituted by the second transmembrane 
helix of bacteriorhodopsin, it was suggested that an α-helical transmembrane conformation is 
important for the biological function of SP-C, while the exact amino acid sequence of the 
transmembrane helix is of less importance (168). 
Based on the results with the SP-C/bacteriorhodopsin hybrid, another analogue called SP-
C(Leu) was created by substituting every helical valine by leucine (that favors α-helix 
conformation), and replacing the palmitoylated cysteines by serines (to avoid unwanted 
disulfide bridges in the absence of palmitoyl-Cys) (Table 5). A method for chemical acylation 
of SP-C analogues has been developed (169) but palmitoylated SP-C(Leu) did not show better 
activity than the non-acylated peptide in a rabbit model of RDS (144). For this reason and the 
added complexity of synthesizing acylated SP-C analogues, further analogues all have had Ser 
instead of palmitoyl-Cys.  
SP-C(Leu) was shown to have an α-helical content and surface-active properties in vitro similar 
to those of native SP-C. It was also shown that a mixture of synthetic phospholipids and 2% 
SP-C(Leu) improved lung dynamics in preterm rabbit fetuses, an RDS model, in comparison 
to non-treated controls. However, SP-C(Leu) can form helical oligomers, a property that differs 
compared to the mainly monomeric form of native SP-C under the same conditions (170). It 
has indeed been shown that SP-C with a poly-valine sequence can form a dimer, mediated by 
a motif in the C-terminal part (95, 145) but higher order oligomers as observed for SP-C(Leu) 
are likely less functional than monomers. In order to avoid oligomerization of SP-C(Leu), three 
lysines spaced with four residues were introduced. This analogue was called SP-CLKS and it 
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was shown to promote phospholipid adsorption to an air/water interface in vitro (171). 
However, SP-CLKS did not improve lung function in the premature rabbit RDS model (144) 
and therefore yet another analogue with only one added lysine in the beginning of the poly-
leucine region, deletion of the two N-terminal residues (resulting in a 33-residue peptide) was 
designed, referred to as SP-C33. SP-C33 did not show oligomerization and in mixture with 
phospholipids it was as active as the natural derived surfactant Curosurf® in a premature rabbit 
model of RDS, provided that a positive end expiratory pressure (PEEP) was applied during 
artificial ventilation (144). Later on, it was shown that in the absence of PEEP, surfactants 
containing both SP-C33 and native SP-B, or Mini-B, were more active in an animal model of 
neonatal RDS than surfactant preparations containing only SP-C33 or only SP-B (56, 57). 
Additional peptide and peptoid analogues of SP-C and SP-C(Leu) have been designed and 
analyzed, but for the same reason as for non-peptide SP-B analogues they are not described in 
here. A recent review of the development of synthetic surfactant preparations describe these 
analogues in detail (95).  
Finally, SP-C33Leu (Figure 6) is an SP-C analogue similar to SP-C33 but the methionine in 
position 31 has been substituted by leucine, in an analogous manner as Mini-BLeu was created 
to avoid unintentional oxidation. SP-C33Leu is structurally similar to SP-C33 and it has been 
shown to be as active as Curosurf® in vitro and in vivo (172-174).  
 
Figure 6. Three-dimensional structure of the SP-C analogue SP-C33Leu determined in 
organic solvents. Cartoon representation of the polypeptide backbone. N and C indicate the 
N- and C- terminus of the peptide respectively. PDB code: 5NDA (172). 
 
 
N
C
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Table 5. Comparison of amino acid sequences of human SP-C and SP-C analogues. The two 
Cys in yellow in human SP-C are palmitoylated. The sequence differences of the SP-C 
analogues from the human SP-C are marked in red. 
 
 
1.9 Synthetic lung surfactants 
As described above several lung surfactants containing synthetic phospholipids and different 
single peptides, for example, recombinant SP-C, Mini-B, Super Mini-B, SP-C(Leu), or SP-C33 
have been created over the years. These surfactants have overall shown good results in vitro 
and in vivo and it has been shown that synthetic surfactants containing analogues of both SP-B 
and SP-C are more efficient than surfactants with only one peptide analogue (56, 143, 175). 
A synthetic surfactant preparation called CHF5633, containing both Mini-BLeu (0.2%) and 
SP-C33Leu (1.5%) mixed with DPPC:palmitoyl-oleyl-phosphatidylglycerol (POPG) (1:1, 
w/w)) is now in clinical trials (174). CHF5633 is as good, or better than animal-derived 
surfactants in rabbit and lamb models of preterm RDS or surfactant inhibition, respectively 
(173, 176).  
The cost and therefore the availability of a synthetic surfactant can potentially be reduced if the 
peptide analogues are produced recombinantly instead of by chemical synthesis. In addition, 
Polypeptide Sequence
1           10           20            30  
Human SP-C FGIPCCPVHLKRLLIVVVVVVLIVVVIVGALLMGL
rSP-C FGIPFFPVHLKRLLIVVVVVVLIVVVIVGALLMGL
SP-C/bacteriorhodopsin FGIPCCPVHLKRFYAITTLVAAIAFTLYLSLLLGY
SP-C(Leu) FGIPSSPV-LKRLLILLLLLLLILLLILGALLMGL
SP-CLKS FGIPSSPVHLKRLLILKLLLLKLLLLKLGALLMGL
SP-C33 --IPSSPVHLKRLKLLLLLLLLILLLILGALLMGL
SP-C33Leu --IPSSPVHLKRLKLLLLLLLLILLLILGALLLGL
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chemical synthesis can result in truncated versions of the peptide or other by-products that can 
be difficult to remove. Therefore, recombinant production of SP-B and SP-C analogues is an 
attractive strategy, which we have explored in papers II, III and IV of this thesis. 
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2 THIS STUDY 
 
2.1 Aims 
The main and overall aim of this thesis was to develop surfactant protein analogues that 
combined with simple phospholipid mixtures can be used to treat neonatal RDS and ARDS in 
animal models, with at least the same efficiency as natural derived surfactant preparations. 
The four individual projects of this thesis were based on the following more specific aims: 
• to design SP-B analogues with different intramolecular disulfide patterns and study the 
effects of mixtures of each of these analogues with an SP-C analogue and phospholipids 
in a rabbit fetus model of neonatal RDS (Paper I). 
 
• to optimize the purification process of recombinant SP-C33Leu, mix the purified 
peptide with synthetic phospholipids to obtain a cost-efficient synthetic pulmonary 
surfactant (rSP-C33-surfactant) (Paper II), and to evaluate it in animal models of 
neonatal RDS (Paper II) and ARDS (Paper III).  
 
• to design, produce, purify and analyse novel analogues that potentially combine the 
properties of SP-B and SP-C in one polypeptide chain and to investigate if mixtures of 
these Combo peptides with phospholipids are functional in a rabbit model of neonatal 
RDS, even in the absence of lung-stabilising ventilation with PEEP (Paper IV). 
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2.2 Methods 
 
This section is a summary of the salient features of the more unconventional methods used in 
papers I-IV. For a more complete description see the material and methods sections of the 
respective papers.  
 
Modified N-terminal domain (NT) from spidroins as solubility tag for recombinant 
protein production 
The target proteins produced recombinantly in papers II, III and IV have been expressed as 
fusion proteins using solubility tags to enhance their solubility and avoid aggregation during 
expression. The solubility tags used were NT* (also called NT*MaSp) in papers II and III and 
FlSpNT* (also called NT*FISp) in paper IV. These tags are based on the N-terminal domain 
(NT) of two different spider silk proteins (spidroins) developed by our group, from the idea 
that NT works as a solubility enhancer that keeps the aggregation-prone spidroins in solution 
during storage in the silk gland (172, 177). During spider silk formation NT dimerizes (178, 
179) and in order to avoid dimerization NT* in which Asp40 was substituted with Lys and 
Lys65 with Asp was developed (172, 180, 181). In addition to being a constitutive monomer, 
NT* is very stable and hypersoluble, and can successfully be used to produce recombinant, 
active SP-C33Leu (rSP-C33Leu) in E. coli (172). 
 
Alkaline hydrolysis and two-phase separation 
For purification of peptides, the bacterial lysates obtained after recombinant production in 
paper IV, were subjected to alkaline hydrolysis using 0.2 M KOH at 40°C for 60 min. The ester 
bonds in the lipids (see Scheme 1) are cleaved forming above all free fatty acids,  glycerol,  and 
phosphoric acid. Following the hydrolysis, a two-phase separation was performed using 
chloroform/methanol/water 8:4:3 (by volume). The lower phase was washed by removing the 
upper phase and adding more methanol/water 1:1 to create a new upper phase. The upper phase 
contained most of the hydrolyzed lipids while the peptide stayed in the lower organic phase. 
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Lipidex-5000 chromatography 
Reverse phase Lipidex-5000 liquid chromatography was used in papers II, III and IV in order 
to separate the target peptides from remaining lipids. Samples resuspended in 
methanol:dichloroethane:water, 85:10:5 (by volume) in papers II and III and in 
methanol/ethylene chloride/0.1 M HCl, 85:10:5 (by volume) in paper IV were applied to a first 
Lipidex-5000 column. The first column volume was collected, dried, resuspended in the same 
solvent and subjected to separation with higher resolution using a longer Lipidex-5000 column 
than the first one. The fractions containing the target peptide were selected from the appearance 
of Coomassie stained bands after SDS-PAGE. In the reverse phase Lipidex-5000 column the 
polypeptides are expected to elute early followed by the phospholipids and finally by neutral 
lipids. The use of an acidic mobile phase in paper IV was intended to acidify the peptide and 
therefore reduce the risk of aggregation. 
 
Sephadex LH 60 chromatography 
In paper IV, the components obtained after the Lipidex-5000 chromatography gave rise to two 
bands in the same fractions, observed by SDS-PAGE, that were possible to separate in the 
Sephadex LH 60 column. Sephadex LH 60 is a size exclusion lipophilic column that can be 
used to separate lipophilic molecules in organic solvents, for example, lipids and small peptides 
(51). The sample (that contained two bands) obtained from the second column of Lipidex-5000 
in the purification of Combo peptide 6 in paper IV was dried, resuspended in 
chloroform/methanol/0.1 HCl, 19:19:2 (by volume) and applied to a Sephadex LH 60 column. 
Combo peptide 6 was identified as the upper band on SDS-PAGE and eluting first on Sephadex 
LH 60 chromatography, by using N-terminal sequence analysis by Edman degradation.  
 
Synthetic surfactant mixtures 
Different percentages (0.75-8%, by weight) of the peptides obtained after chemical synthesis 
in papers I and IV and recombinant expression and purification in papers II, III and IV were 
mixed with phospholipids to create different synthetic surfactants. We used two different 
phospholipid compositions: DPPC/egg yolk-PC/POPG, 50:40:10 (by weight) that has been 
shown to be effective in previous studies (143) and DPPC/POPG, 50:50 (by weight) that is 
used in the synthetic surfactant CHF5633 (173). Dried phospholipids and dried peptides were 
resuspended in chloroform/methanol, 2:1 (by volume) and mixed. After drying the samples 
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carefully under reduced pressure, they were resuspended in physiological saline (154 mM NaCl 
in water) to 80 mg/ml of phospholipids. 
 
RDS rabbit model 
The RDS premature rabbit fetus model essentially as introduced by Enhörning and Robertson 
(8) was used in papers I, II and IV. This model was used to test the mechanical properties of 
the lungs of premature rabbit fetuses with RDS after tracheal instillation of different pulmonary 
surfactant preparations (Figure 7). The animals were ventilated after the instillation of 
surfactant, with the help of a ventilator using high pressures, which creates tidal volumes that 
are much higher than the physiological values. This is a good screening model to evaluate the 
in vivo activity of exogenously delivered surfactant. Animals that are not instilled with any 
surfactant mixture are used as negative controls and should have very low tidal volumes and 
thus low lung compliance, to verify the immaturity of the litter. The lung gas volumes are a 
quantification of the residual gas inside the lungs after the end of mechanical ventilation, and 
are measured using a water displacement technique (182). The studies to test the surfactant 
preparations containing phospholipids only or phospholipids and the SP-C analogue rSP-
C33Leu (i.e. no SP-B analogue present) were performed with PEEP (papers II and III), while 
the studies that were aimed to test surfactants containing phospholipids and two peptide 
analogues (paper I) or one analogue that is designed to combine the properties of both SP-C 
and SP-B (paper IV) were performed without PEEP. Even though the use of PEEP is extensive 
in the clinics to improve oxygenation and prevent alveolar collapse, the absence of PEEP can 
better asses the performance of a pulmonary surfactant. Previous studies have shown that a 
synthetic pulmonary surfactant containing all three essential elements (phospholipids, SP-B or 
SP-B variant  and SP-C or SP-C variant) is able to achieve results similar to natural derived 
surfactants in the RDS rabbit model without PEEP (56, 57, 143), while the same surfactant 
lacking the SP-B or the SP-C element needs PEEP to achieve similar results (172, 183). 
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Figure 7. Timeline of the RDS animal experiments. The animals were tracheotomized and 
treatment was administrated before placing the animals in the ventilator. The animals were 
ventilated during 30 min with air at different pressures followed by 5 min of ventilation with 
N2 at 25 cmH2O. The animals were sacrificed and the lungs were excised to measure the lung 
gas volumes. 
 
ARDS rabbit model 
An adult rabbit model of ARDS was developed in paper III. This animal model includes mild 
lung lavages that do not remove endogenous surfactant completely and induces an ARDS like 
state via ventilator induced lung injury (VILI), i.e. injurious ventilation that causes epithelial 
damage via high tidal volumes and low PEEP.  
This model was used to test the ability of a synthetic surfactant based on only rSP-C33Leu to 
restore lung function and reduce inflammation after ARDS induction, and after treatment the 
animals were ventilated with physiological tidal volumes and PEEP.  
 
Rabbit as model for RDS and ARDS 
There is no perfect animal model that can be used to completely simulate a human lung 
disorder. However, there are some models that are better than others. Rabbits have been shown 
to be good candidates to simulate RDS and ARDS. The rabbit is phylogenetically closer to 
humans than mice or guinea pigs and cheaper than pigs and monkeys, and their relatively big 
size allows the study of lung mechanics even in premature fetuses. Anatomically the lungs of 
rabbits and humans are similar, with trachea, bronchi, bronchioles and alveoli but important 
differences are present. For example: the rabbit does not possess respiratory bronchioles, the 
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human lung is more vascularized than the rabbit lung, with seven capillaries per mm compared 
to five in rabbits, the human airway branching has less number of generations compared to the 
rabbit branching, and the two new airways generated in every branching have almost the same 
diameter in humans, but different diameters in rabbits (184). 
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3 RESULTS AND DISCUSSION 
 
The development of synthetic surfactant preparations for the treatment of RDS has been 
ongoing for about 30-40 years. The research has evolved from the first synthetic surfactants 
that only contained phospholipids to mixtures of phospholipids with one or two surfactant 
protein analogues. In spite of all this effort, the development of synthetic surfactants is still a 
challenge. The native pulmonary surfactant is hard to replicate and produce because first, the 
lipid composition is very complex with multiple and diverse lipid species and second, the two 
hydrophobic lung surfactant proteins SP-B and SP-C are particularly hard to reproduce. During 
the last 30 years the main focus has been on the development and production of SP-B and SP-
C analogues. 
In paper I, we investigated the possibility to develop an SP-B analogue that lacks cysteines and 
therefore can not form disulfide bridges, for the reason that such analogues will likely be more 
straightforward to synthesize since inadvertent intermolecular disulfide pairings and need for 
Cys side-chain blocking groups are avoided. We evaluated in vivo the importance of the two 
disulfide bridges in an SP-B analogue called Mini-B27. Different versions of Mini-B27 with 
two, one or no intramolecular disulfide bridges (Figure 8) were mixed with the SP-C analogue 
SP-C33Leu and phospholipids, to form synthetic surfactants that were investigated in a 
premature rabbit fetus model of RDS. Curosurf® was used as positive control and untreated 
fetuses were used as an indication of immature animals that fulfill the criteria for RDS.  
Mini-B27 was designed with the idea of creating an analogue similar to Mini-B, that was 
already proven to have good in vivo activity (56, 150), but containing a shorter and therefore 
probably more stable loop connecting the two α-helices. The stable turn could potentially 
maintain the hairpin structure of Mini-B27 even in the absence of the covalent disulfide bonds 
connecting the cysteine residues of each helix in Mini-B. The development of an active SP-B 
analogue without cysteines would be of interest because of the possibility to scale up its 
production in a cost-efficient manner.  
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Figure 8: Schematic representations of the four SP-B analogues and their different half-
cystine content used in paper I. SP-B analogues containing two (Mini-B27), one inner or outer 
(Mini-B27i and Mini-B27o), or no (Mini-B27w) intramolecular disulfide bridge(s) were 
studied. 
 
Synthetic surfactant containing Mini-B27 with two intramolecular disulfide bridges was shown 
to give lung gas volumes similar to Curosurf® indicating a good ability to reduce alveolar 
surface tension and prevent alveolar collapse at the end of expiration. The synthetic surfactants 
containing Mini-B27 versions with one or no intramolecular disulfide bridges all showed an 
inferior ability to avoid alveolar collapse at the end of expiration (Figure 9). The results of 
paper I indicate that the presence of at least two disulfide bridges in Mini-B27 are important to 
create high lung gas volumes and avoid alveolar collapse at the end of expiration. 
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Figure 9. Lung gas volumes of the animals treated with pulmonary surfactants that included 
Mini-B27 analogues containing different disulfide patterns. Curosurf® was used as positive 
control and the untreated controls (no treatment) were used to confirm lack of sufficient 
endogenous surfactant in the animals. The synthetic surfactants contained phospholipids, 2% 
SP-C33Leu and 2% of Mini-B27, Mini-B27w, Mini-B27i, or Mini-B27o. The histograms and 
the error bars indicate the median values and the interquartile range, respectively. *** p ≤ 
0.001 against both Curosurf® and Mini-B27. Data from paper I. See Figure 8 for primary 
structures of the Mini-B27 analogues. 
 
Another study, published a few months before paper I, developed an SP-B analogue based on 
Super Mini-B, called B-YL, where the cysteines were substituted by tyrosines suggesting that 
the hairpin structure could be maintained by aromatic interactions between the tyrosines (153). 
The in vitro and in vivo results shown by Walther et al. (153) differ from those in paper I in the 
sense that B-YL is as active as Curosurf®, suggesting that the design of an active SP-B analogue 
lacking cysteines is indeed possible. There are many differences between the studies in paper 
I and Walther et al. (153), for example peptide design (Mini-B vs Super Mini-B), surfactant 
lipid composition and animal model, that could contribute to the different results obtained.  
In paper II, we optimized the purification method of the recombinant SP-C analogue, rSP-
C33Leu by including a chromatography step that removes lipid contaminants. The non-
chromatographic purification of rSP-C33Leu previously described by Kronqvist et al. (172) 
efficiently isolated rSP-C33Leu from protein impurities, and by adding a two-step Lipidex-
5000 chromatography we further removed non-protein contaminants that correspond to about 
90% of the weight of the initially purified sample. The pure peptide was mixed with 
phospholipids (DPPC:egg yolk-PC:POPG in 50:40:10) to produce a surfactant that was then 
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tested in a premature rabbit fetus model of RDS (paper II) and in an adult rabbit model of 
ARDS (paper III).  
In the rabbit model for neonatal RDS, the porcine derived surfactant Curosurf® was used as 
positive control, untreated fetuses were used to verify immaturity and presence of an RDS like 
state (very low lung compliance and low lung gas volumes at the end of the ventilation period). 
A mixture of only phospholipids (DPPC:egg yolk-PC:POPG in 50:40:10) was used to verify 
the importance of the presence of rSP-C33Leu. The premature rabbits treated with the 
surfactant containing 2% of rSP-C33Leu showed tidal volumes and lung gas volumes lower 
than the animals treated with Curosurf® but higher than the ones treated with only 
phospholipids (Figure 10). These results indicate that the synthetic surfactant containing rSP-
C33Leu is able to improve the lung mechanics compared to a mixture of only phospholipids.  
 
 
Figure 10: Lung gas volumes after treatment of a premature rabbit model of RDS with rSP-
C33Leu surfactant and controls. Lung gas volumes calculated after ventilation with PEEP of 
untreated animals (no treatment), or animals treated with the synthetic surfactants containing 
phospholipids and rSP-C33Leu (rSP-C33Leu surfactant) or only phospholipids 
(Phospholipids), or the porcine derived surfactant Curosurf®. The histograms and the error 
bars indicate the median values and the interquartile range respectively. *** = p ≤ 0.001 and 
**** = p ≤ 0.0001. Data from paper II. 
 
It is important to mention that the animal experiments described in paper II were performed 
using PEEP, which is required for optimal effect of surfactants that express only the properties 
of one surfactant protein and is commonly used in clinical treatment of RDS and ARDS 
patients. A synthetic surfactant created with phospholipids and 2% of the SP-C analogue SP-
C33, which is structurally similar to SP-C33Leu (Table 5), was shown to give similar lung gas 
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volumes (median >10ml/kg) and tidal volumes as our rSP-C33Leu surfactant in the same RDS 
animal model when PEEP was applied (183). However, when PEEP was not applied the 
mixture of phospholipids and 2% SP-C33 showed significantly lower lung gas volumes 
(median <5 ml/kg) (56, 57). Also when SP-B or an analogue thereof was added to the mixture 
the lung gas volumes in the absence of PEEP were similar to the ones now obtained with our 
rSP-C33Leu surfactant in the presence of PEEP (median >10ml/kg) (56, 57, 143).  
Even though an optimal effect of a synthetic surfactant is obtained only when compounds with 
properties of both SP-B and SP-C are present, rSP-C33Leu surfactant can be clinically relevant 
since it can achieve high lung gas volumes when PEEP is applied, and the possibility of 
producing SP-C33Leu recombinantly makes the surfactant production possible to scale up, for 
example to enable treatment of ARDS patients, as investigated in another rabbit model in paper 
III.  
In paper III, synthetic pulmonary surfactant containing rSP-C33Leu was used in adult rabbits 
that were subjected to repeated bronchoalveolar lavages (BAL) followed by injurious 
ventilation in order to reduce oxygenation and induce an ARDS like state. Treatment with 
Curosurf® was used as a positive control and treatment with air as negative control. In this 
study we showed that the surfactant containing rSPC33Leu was able to increase oxygenation 
levels and reduce inflammation and edema in a similar manner as Curosurf®. Previous studies 
also investigated the use of synthetic surfactants in the treatment of ARDS showing an increase 
in oxygenation and dynamic compliance in lung-lavaged, surfactant deficient rats (141) and 
rabbits (140). 
ARDS is characterized by capillary endothelium and alveolar epithelium damage, which leads 
to reduced alveolar surfactant activity and oxygenation, and creates an inflammatory state that 
leads to respiratory failure (185). In spite of that extensive research efforts have gone into 
evaluation of exogenous surfactant therapy to treat ARDS, clinical studies and meta-analysis 
thereof have failed to show improvement of mortality (186). However, we suggest that the 
activity of rSP-C33Leu surfactant observed in paper III, in combination with the possibility 
that its production could be scaled up, motivate further attempts to modify it so that resistance 
to inactivation by plasma components is increased. One possible way forward could be to 
screen for compounds that increase resistance to inactivation using in vitro surface activity 
measurements, and then study the most promising ones in the adult rabbit model of ARDS 
introduced in paper III. However, the results obtained in paper IV probably motivates to rather 
begin screening efforts for inhibitors of surfactant inactivation from an optimized Combo 
peptide-based surfactant. The results in paper IV showed that surfactants containing Combo 
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peptides are equal to natural derived surfactant also in the absence of PEEP, which is not the 
case for rSP-C33Leu surfactant. 
In paper IV, we designed six different pulmonary surfactant protein analogues, called Combo 
peptides, based on the idea to combine properties of both SP-B and SP-C in one polypeptide 
chain. The Combo peptides were produced either by organic synthesis (Combo peptide 1) or 
by recombinant production (Combo peptides 2-6), and mixtures of each Combo peptide with 
phospholipids were tested in the rabbit model of neonatal RDS without PEEP. The architecture 
is similar for all Combo peptides; an N-terminal SP-B analogue part, followed by a linker and 
the SP-C analogue SP-C33Leu (Table 6). The sequence of the SP-B analogue and/or linker 
segment varied in the respective Combo peptides. The SP-B analogue in Combo peptide 1 was 
based on the first helix of Mini-BLeu, the sequence of Combo peptide 2 is based on Super 
Mini-B, and the sequences of Combo peptides 3-6 are based on full length Mini-BLeu. 
However, further modifications were introduced; in the Combo peptides all or half of the 
cysteines present in Mini-BLeu and Super Mini-B have been mutated to leucines to increase 
hydrophobicity, reduce complexity and avoid the formation of unwanted disulfide bridges. 
Combo peptides 1 and 3-5 do not contain any cysteine, while Combo peptides 3 and 6 contain 
2 cysteines. Also, in Combo peptide 2 the methionines were mutated to leucines to avoid 
unintentional oxidation. The SP-B analogues present in Combo peptides 3 and 4 are similar to 
those in 6 and 5 respectively, however in Combo peptides 6 and 5 all the lysines have been 
substituted by arginines to avoid possible inadvertent acylation of the Lys side-chain amino 
group (187). Two linker versions were used, a short (GSG) in Combo peptides 1, 3-6 and a 
long (GSGSGSGS) in Combo peptide 2. The sequence of the SP-C analogue is constant in all 
Combo peptides and corresponds to SP-C33Leu that was studied in papers II and III with the 
exception of Combo peptides 5 and 6 where the lysines in SP-C33Leu were substituted by 
arginines (Table 6). 
 
 
 
 
 
 
  35 
 
 
Table 6. Amino acid sequences of the Combo peptides studied in paper IV. The SP-B 
analogue parts are colored in light blue, the linkers in green and the SP-C analogue parts in 
dark blue. The amino acid residues are shown by their one letter code. The lysines mutated to 
arginines in Combo peptides 5 and 6 and the cysteines are marked in red. 
 
 
The Combo peptides were designed with the idea of creating a synthetic pulmonary surfactant 
that contains only one protein component and a simple phospholipid mixture, and still is as 
efficient against RDS as animal derived surfactants like Curosurf®. The presence of only one 
protein component is beneficial from a regulatory point of view and could potentially reduce 
the cost of production of the pulmonary surfactant, allowing to expand its possible use to other 
lung diseases.  
The Combo peptide 1 was made by chemical synthesis and Combo peptides 2-6 were produced 
and purified recombinantly. The purification procedure for Combo peptides 2-6 was based on 
the purification described for rSP-C33Leu in paper II, with some modifications. Hydrolysis 
and two-phase separation were introduced to hydrolyze phospholipids and isolate the target 
peptide from released fatty acids, glycerol, alcohols and phosphate groups. Also, the addition 
of Sephadex LH 60 chromatography enabled us to separate the peptide from unknown 
contaminant(s), which migrated as a lower band on SDS-PAGE and stained with Coomassie 
Brilliant Blue dye.  
Each Combo peptide was mixed with phospholipids and the surfactants obtained were used in 
the premature rabbit model for RDS described above. Curosurf® was used as positive control 
and the mixture of phospholipid only was used as negative control. Also, animals that did not 
                      SP-B analogues                                Linker                    SP-C33Leu
Combo peptide 1 -------LWLLRALIKRIQALIPKG-----------------GSG-----IPSSPVHLKRLKLLLLLLLLILLLILGALLLGL
Combo peptide 2 FPIPLPYLWLLRALIKRIQALIPKGGRLLPQLVLRLVLRLS-GSGSGSGSIPSSPVHLKRLKLLLLLLLLILLLILGALLLGL
Combo peptide 3 -------LWLCRALIKRIQALIPKGGRLLPQLVCRLVLRLS-GSG-----IPSSPVHLKRLKLLLLLLLLILLLILGALLLGL
Combo peptide 4 -------LWLLRALIKRIQALIPKGGRLLPQLVLRLVLRLS-GSG-----IPSSPVHLKRLKLLLLLLLLILLLILGALLLGL
Combo peptide 5 -------LWLLRALIRRIQALIPRGGRLLPQLVLRLVLRLS-GSG-----IPSSPVHLRRLRLLLLLLLLILLLILGALLLGL
Combo peptide 6 -------LWLCRALIRRIQALIPRGGRLLPQLVCRLVLRLS-GSG-----IPSSPVHLRRLRLLLLLLLLILLLILGALLLGL
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receive any treatment were used as controls to confirm the lack of endogenous surfactant and 
RDS like state of each litter. The results showed that pulmonary surfactants containing 3% 
(w/w) of Combo peptide analogues achieve high lung gas volumes and high tidal volumes in 
the absence of PEEP (Figure 11). The absence of PEEP is a more demanding model and is thus 
an informative way of assessing the activity of the surfactant in our RDS rabbit model. It is 
also interesting to mention that in contrast to the results obtained in paper I, pulmonary 
surfactants containing Combo peptides 2 and 4 that lack cysteines are able to produce lung gas 
volumes and tidal volumes very similar to Curosurf®. 
 
 
Figure 11. Lung gas volumes of animals after instillation of pulmonary surfactants 
containing 3% Combo peptide 2-6 and ventilation without PEEP. Curosurf was used as 
positive control and the untreated controls were used to detect lack of sufficient endogenous 
surfactant in the animals. The histograms and the error bars show the median and the 
interquartiles, respectively. **** = p ≤ 0.0001. Data from paper IV. 
 
Native mammalian pulmonary surfactant contains about 2% by dry weight of each 
hydrophobic surfactant protein (2% of SP-B and 2% of SP-C) which corresponds to about 1 
molecule of dimerized SP-B to 4 molecules of SP-C. Natural derived surfactant preparations 
usually contain about 1% or less by dry weight of each surfactant protein (~0.5-1.1%), for 
example Curosurf® contains about 0.6% SP-B and 0.7% SP-C which corresponds to about 1 
molecule of dimerized SP-B to 5 molecules of SP-C. The synthetic surfactant in clinical trials 
CHF5633 contains 0.2% of the SP-B analogue Mini-BLeu and 1.5% of the SP-C analogue SP-
C33Leu, which in this case corresponds to about 1 molecule of Mini-BLeu per 7 molecules of 
SP-C33Leu. The synthetic production of SP-C33Leu and especially Mini-BLeu are 
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complicated and thus expensive, which probably affects the amount of protein analogues in 
CHF5633. The surfactants containing Combo peptides, per design, contain 1 SP-B analogue 
domain per 1 SP-C analogue domain, and a 3% Combo peptide surfactant that showed similar 
activity to Curosurf® contains about 1.5% by dry weight of each surfactant protein analogue 
domain. The protein quantity in the synthetic surfactants containing Combo peptides are thus 
comparable to native pulmonary surfactant. 
There are not yet any structural data for the Combo peptides, but we hypothesize that the SP-
B analogue domain and the SP-C analogue domain can interact independently with the 
phospholipids of surfactant. The Combo peptides could thus tentatively bind to different 
phospholipid (bi)layers (Figure 12), allowing membrane fusion, rapid transport between 
membranes and membrane stabilization during exhalation.  
 
 
Figure 12. Hypothetical model of a Combo peptide interacting with phospholipids of 
pulmonary surfactant. The SP-B analogue domain is represented by the Mini-B structure in 
light blue (pdb: 2DWF) the linker is shown as a green line and the SP-C analogue domain is 
illustrated by the SP-C33Leu structure in dark blue (pdb: 5NDA). Adapted from paper IV. 
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Combo peptides and the possibility to produce them recombinantly is a potential breakthrough 
in the development of synthetic pulmonary surfactants. The production of recombinant SP-C 
analogues has already been reported, but the production of recombinant SP-B analogues has to 
our knowledge never been published, and in our hands recombinant expression of Mini-B using 
the NT* tag was unsuccessful (unpublished observations). The Combo peptides thus offer the 
first recombinant expression of a protein containing an SP-B analogue domain.  
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4 CONCLUSIONS 
 
• A pulmonary surfactant containing 2% Mini-B27, 2% SP-C33Leu and phospholipids 
can achieve high lung gas volumes in a premature rabbit model of RDS, provided that 
the Mini-B27 peptide contains at least two intramolecular disulfide bridges. 
 
• The purification of recombinant SP-C33Leu can be improved by adding a two step 
Lipidex-5000 chromatography that removes lipid contaminants. 
 
• A pulmonary surfactant containing phospholipids and 2% of recombinant SP-C33Leu 
gives high lung gas volumes and tidal volumes in a premature rabbit model of RDS, as 
well as increased oxygenation and reduced inflammation and oedema in an adult rabbit 
model of ARDS. 
 
• The production of recombinant Combo peptide analogues that harness properties of 
both SP-B and SP-C in one polypeptide chain is possible. 
 
• Mixtures of 3% Combo peptide analogues with phospholipids give high tidal volumes 
and high lung gas volumes in a premature rabbit model of RDS in the absence of PEEP, 
which is comparable to the results obtained with a natural derived surfactant preparation 
and superior to those obtained by synthetic surfactant based on single surfactant peptide 
analogues. 
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5 FUTURE PRESPRECTIVES 
 
Despite the increasing knowledge on surfactant protein structure and function as well as the 
advances in development of hydrophobic surfactant protein analogues, there are still important 
questions that need to be resolved in order to enable rational design of synthetic surfactant. 
First, the specific activities and mechanisms of action of SP-B and SP-C are still not well 
understood, nor are their molecular interactions with surfactant phospholipids. Second, the 3D 
structure of native SP-B has not been resolved and there are severe limitations to the proposed 
structural models, mainly because SP-B differs in many ways from the proteins on which it has 
been modelled and only low-resolution structural data on SP-B is available. Third, the optimal 
phospholipid mixture that should be the base for synthetic surfactants is unknown. Fourth, an 
SP-B analogue that can be cost-efficiently produced and that lacks disulfide bonds to avoid 
intermolecular disulfides and complicated synthesis is not available. These are important 
research questions to tackle in the near future, not only to enable replacement of natural derived 
surfactant preparations for treatment of neonatal RDS, but also because the development of a 
cost-efficient synthetic surfactant could realize the since long held possibility to develop a 
surfactant for therapy of also other diseases such as ARDS, where high amounts of surfactant 
that is resistant to inactivation is needed, or lung infections where surfactant could be used as 
a carrier for drugs into the airways. 
We believe that the work presented in this thesis brings us a bit closer to achieving some of 
these important goals. Even though there is still a lot of research to be done to optimize the 
preparations and understand the molecular behavior of the peptide analogues, the synthetic 
surfactants containing Combo peptides could potentially be used for both RDS and ARDS. The 
fact that these preparations contain only one peptide and that this peptide can be produced 
recombinantly could optimize the production yield and cost, resulting in a viable large-scale 
production. In addition, this synthetic surfactant could be modified by adding molecules that 
could increase the resistance to inactivation, such as SP-A and SP-D or, more likely, synthetic 
analogues thereof. Synthetic surfactant containing Combo peptides could also be used as a drug 
carrier by mixing it with for example antibiotics or antimicrobial peptides to treat lung 
infections. The drugs could thus be efficiently transported to the alveoli using the excellent 
spreading and adsorption properties of pulmonary surfactant, avoiding systemic effects and 
potentially reducing the amount of drug administrated. Therefore, we speculate that surfactants 
containing Combo peptides could be used to treat RDS and other lung diseases.  
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“When you are studying any matter, or considering any philosophy, ask yourself only what are 
the facts and what is the truth that the facts bear out. Never let yourself be diverted, either by 
what you wish to believe, or by what you think would have beneficent social effects if it were 
believed. […] Love is wise, hatred is foolish. In this world, which is getting more and more 
closely interconnected, we have to learn to tolerate each other, we have to learn to put up with 
the fact that some people say things that we don’t like. We can only live together in that way—
and if we are to live together and not die together—we must learn a kind of charity and a kind 
of tolerance, which is absolutely vital to the continuation of human life on this planet.”  
Bertrand Russell (1872 - 1970) 
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